Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
(NASDAQ:ALNY) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC)
Related Questions
How will the initiation of the Phase 3 CVOT for zilebesiran influence Alnylam's stock momentum and trading volume?
What are the anticipated timelines for data read‑out and potential FDA/EMA submission, and how could those milestones affect valuation?
How does the KARDIA Phase 2 data and upcoming Phase 3 trial position zilebesiran against other RNA‑i or cardiovascular‑focused competitors in terms of market share and revenue potential?